Enhanced SARS-CoV-2 Vaccine Composition and Delivery System

The present inventive concept relates to an improved vaccine composition and delivery system for inducing immunity against SARS-CoV-2, enhancing immunogenicity and efficiency through optimized spike and nucleocapsid protein sequences, endosomal targeting, and lipid nanoparticle encapsulation.

The original patent disclosed a method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid immunogens delivered by a replication-defective adenovirus. However, the original patent had limitations in terms of immunogenicity and efficiency. The present inventive concept addresses these limitations by introducing optimized protein sequences, endosomal targeting, and lipid nanoparticle encapsulation to enhance the immune response and reduce the risk of adverse reactions.

The inventive concept comprises a replication-defective adenovirus vector encoding a CoV2 spike protein sequence optimized for cell surface expression and a nucleocapsid protein CoV2 nucleocapsid protein fused to an endosomal targeting sequence. The vector further comprises a nucleic acid encoding an adjuvant protein to enhance immunogenicity. The vaccine composition can be administered to a patient by delivery to nasal mucosa, in conjunction with an anti-SARS-CoV-2 vaccine injection. The lipid nanoparticle encapsulation enhances the transduction efficiency of the adenovirus vector, leading to a more efficient immune response.

The present inventive concept introduces several novel features, including the optimized spike and nucleocapsid protein sequences, endosomal targeting, and lipid nanoparticle encapsulation. These features are not obvious from the original patent and provide a significant improvement in immunogenicity and efficiency.

Alternative embodiments of the inventive concept include varying the type of adenovirus vector, the specific protein sequences, and the method of administration. Additionally, the inventive concept can be adapted for use with other viruses or diseases, providing a broad platform for vaccine development.

The inventive concept has significant commercial potential in the vaccine market, particularly in the context of the ongoing COVID-19 pandemic. The improved immunogenicity and efficiency of the vaccine composition and delivery system make it an attractive solution for governments, healthcare organizations, and pharmaceutical companies seeking to develop effective vaccines against SARS-CoV-2.